Back to Search Results- Recruiting
- Observational
- Chinese University of Hong Kong
- 18 - 80 Years
Study Purpose
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.
Intervention
N/A
Eligibility Requirements
Adult men 18-80 years old
With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
Planned for ADT for at least 1 year
Minimum age: 18
Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation
Prior neoadjuvant or adjuvant hormone therapy within 1 year before
Refuse or unable to give written informed consent
Participation in an investigational program with interventions outside of routine clinical practice
Recruiting status
Recruiting
Estimated enrollment
130
Study start date
Dec 10, 2023
Study end date
Mar 31, 2029
Last updated
Mar 23, 2025
Primary purpose
N/A
Design
Observational
Intervention
Study phase
N/A
Allocation
N/A
Sponsor:
Chinese University of Hong Kong
Collaborator:
N/A
Investigator:
N/A
N/A
Publications
21. Ng CF, Wei Y, Ong TA, Chan W, Chu PSK, Huang CY, et al. The changes in metabolic profiles and cardiovascular risk in Asian prostate cancer patients after androgen deprivation therapy - a prospective real-life evaluation. Int J Urol 2020; 27 S1: UOP-1430.
1. Hong Kong Cancer registry - Prostate cancer in 2020 https://www3.ha.org.hk/cancereg/pdf/factsheet/2020/prostate_2020.pdf
Websites
N/A
NCT06163924
| Clinic | Location | Investigator | Distance | RECRUITING STATUS | Contact |
|---|